Payment overview · 2025
General Payments
$681.28
22 reported records · 5 companies
Healthcare provider profile · identity verified
Charles Frederick Lovell, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NORFOLK, VA · NPI 1174629448
Verified facts
What the public records show
CMS Open Payments records show Charles Frederick Lovell, MD received $681.28 in general payments during 2025 across 22 reported records.
AstraZeneca Pharmaceuticals LP accounted for 35.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $241.83 | 35.5% | 6 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $232.54 | 34.1% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $126.53 | 18.6% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $41.28 | 6.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $39.10 | 5.7% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $681.28 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $232.54 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $149.72 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $126.53 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $92.11 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.28 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $39.10 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 55 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 312 | 96 |
| Atorvastatin Calcium | Atorvastatin Calcium | 275 | 87 |
| Chlorthalidone | Chlorthalidone | 269 | 90 |
| Losartan Potassium | Losartan Potassium | 183 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 164 | 63 |
| Nifedipine Er | Nifedipine | 149 | 39 |
| Spironolactone | Spironolactone | 142 | 56 |
| Ezetimibe | Ezetimibe | 121 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 105 | 37 |
| Metformin Hcl | Metformin Hcl | 100 | 32 |
| Potassium Chloride | Potassium Chloride | 94 | 38 |
| Famotidine | Famotidine | 91 | 33 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 82 | 25 |
| Candesartan Cilexetil | Candesartan Cilexetil | 80 | 26 |
| Valsartan | Valsartan | 78 | 27 |
| Carvedilol | Carvedilol | 77 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 76 | 26 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 75 | 23 |
| Omeprazole | Omeprazole | 72 | 24 |
| Nebivolol Hcl | Nebivolol Hcl | 62 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 61 | 18 |
| Farxiga | Dapagliflozin Propanediol | 55 | 20 |
| Trulicity | Dulaglutide | 49 | suppressed |
| Gabapentin | Gabapentin | 48 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 12 |
| Simvastatin | Simvastatin | 46 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | suppressed |
| Furosemide | Furosemide | 37 | 19 |
| Klor-Con M20 | Potassium Chloride | 37 | 13 |
| Levothyroxine Sodium | Levothyroxine Sodium | 37 | 12 |
| Ozempic | Semaglutide | 36 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 35 | 11 |
| Colchicine | Colchicine | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Allopurinol | Allopurinol | 23 | suppressed |
| Eliquis | Apixaban | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 17 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Veo Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $681.28 · 22 records | AstraZeneca Pharmaceuticals LP | BREZTRI, FARXIGA, JARDIANCE, Korlym, LEQVIO, MOUNJARO, ZEPBOUND | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error